Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Comparative Effectiveness Research: Do Employers Care? What Will They Do? What About Productivity?

This article discusses a survey of employers, conducted by the Benfield Group and supported by the National Pharmaceutical Council, that found that one of the benefits employers are looking for from comparative effectiveness research (CER) is more information about which treatments help with productivity. While data is beginning to emerge regarding the links between good health, productivity and employee wellness programs, this survey shows that most companies (or the benefit consultants they work with) do not have access to the information or any ability to use it in their decision-making.

Specifically, while fewer than one-third of employers or their vendors currently use information about absence, disability and return to work assessing the impact of alternative treatments, 70 percent indicate that such information would be “Important” or “Very Important” within CER. And, while fewer than 25% now use information about the impact of alternative treatments on work productivity in making decisions, over 60% rate this information as “Important” or “Very Important” in CER.

In a more direct analysis of the benefit of CER to employers, respondents were asked how they would handle two specific scenarios related to treatments for low back pain and diabetes. According to the findings, employers are generally more likely to take action based on CER evidence regarding diabetes. The reasons given include the “perceived higher total costs” of treating diabetes and a belief that it would be easier to make changes to address diabetes based on “already generally accepted guidelines for treatment.”

In addition to productivity related information, additional survey findings of note include clear messages about what other types of information employers want: “clinical outcomes of alternative treatments; information comparing utilization and cost of treatments; information about which treatments work best for specific population, and; comparative safety of alternative treatments.”

Although a subscription to the JOEM is required to read this article, the full study, survey instrument and video are available on NPC's website.

Blog Post

CER Tweets of the Week (June 3-7, 2013)

The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...
Newsletter Volume

E.V.I.dently May 2013

Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
YouTube Videos

Why Real-World Evidence Matters

National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...
Blog Post

CER Collaborative: Providing the Tools for Better Formulary Decisions

National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...
Press Release

NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer

WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...
Press Release

NPC Survey Shows Health Care Stakeholders Continue to Show Optimism About Future Role of Comparative Effectiveness Research

(Washington, DC, March 19, 2013)—As the implementation of the Affordable Care Act (ACA) picks up speed, a new survey shows that health care...
Press Release

National Pharmaceutical Council Welcomes Amgen as Its Newest Member

Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...
Press Release

National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards

Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Why Real-World Evidence Matters

National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...
YouTube Videos

CER Collaborative: Assessing Evidence and Informing Decision-Making

National Pharmaceutical Council (NPC) Director of Comparative Effectiveness Research Dr. Jennifer Graff discusses an initiative designed to help...
YouTube Videos

The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making

NPC discusses the findings from its third annual survey that gauges the attitudes and expectations of comparative effectiveness research (CER) among...
YouTube Videos

Taking Patient Variations Into Account

Dr. Lisa Egbuonu-Davis, founder of ROI Squared, explains that data is generally designed toward looking at the mean differences instead of the...
Blog Post

CER Tweets of the Week (June 3-7, 2013)

The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...
Blog Post

CER Collaborative: Providing the Tools for Better Formulary Decisions

National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...
Blog Post

CER Tweets of the Week (Apr. 29 – May 3, 2013)

Conversations on Twitter about evidence and comparative effectiveness research highlighted the Agency for Healthcare Research and Quality’s call for...
Blog Post

The Role of Pharmaceuticals in Health Insurance Exchanges

As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...

Research

Journal of CER

Principles for Planning and Conducting Comparative Effectiveness Research

A group of leading researchers developed a set of 13 best practice principles that could help to...

Effectiveness of Interventions to Improve Patient Compliance: A Meta-analysis

This statistical analysis of 153 studies to explore different approaches of how to improve patient...
  •  
  • 1 of 21
  • >

Commentary & Testimony